Umbilical cord blood (UCB) is an established source of stem cells for transplantation in both adult and paediatric patients with malignant and non-malignant disease who lack a suitable related or unrelated donor (Rocha et al, 2004; Laughlin et al, 2001 ). In the last few years, several independent risk indexes have been proposed with the aim of scoring pre-transplant risk and better predicting outcomes after allogeneic haematopoietic stem cell transplantation (HSCT), including the Haematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) (Sorror et al, 2005) and the European Society for Blood and Marrow Transplantation (EBMT) risk score (Gratwohl et al, 2009) , among other more specific scores (Arora et al, 2011; Weisdorf et al, 2008; Shouval et al, 2015) .
As previously demonstrated, there is considerable heterogeneity in HSCT outcomes, mainly according to the type of disease (Juliusson et al, 2011; Giralt et al, 2011; Hishizawa et al, 2010) and specific disease-related factors that influence outcomes, such as cytogenetics (Armand et al, 2010; Armand et al, 2007) . Recently, one group developed and validated a prognostic score, the disease risk index (DRI), specifically designed for stratifying, according to 4 risk groups, heterogeneous cohorts of patients undergoing HSCT (Armand et al, 2014; Armand et al, 2012) . The DRI takes into account disease type and disease status at transplantation; moreover, it also considers cytogenetics for acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS). This score can be used in patients undergoing HSCT irrespective of age, conditioning intensity regimen and graft source (Armand et al, 2012; Armand et al, 2014) it has also been validated in patients undergoing T-cell depleted HSCT using alemtuzumab (Beauverd et al, 2014) . The DRI has been recently refined by including rare diseases, such as Burkitt lymphomas, and by combining blast percentage, cytogenetics and response to prior therapy for MDS, providing a better risk stratification than the Interantioanl Prognostic Scoring System (IPSS) (Greenberg et al, 1997) for patients undergoing HSCT (Armand et al, 2014) .
Currently, there are no available reports on a large cohort of patients undergoing UCBT. Our aim is to determine the applicability of the DRI for patients undergoing UCBT.
Methods

Data source and definition
This is a retrospective registry study on behalf of Eurocord. Adult patients (18 years or older) with haematological malignancies who underwent single or double UCBT as first allogeneic HSCT in Eurocord/EBMT centres from 2004 to 2014, with available disease-specific data, were included in this study. Patients with more than one haematological disease or with diagnosis of very rare diseases, such as mast cell leukaemia, combined MDS/myeloproliferative neoplasm, were excluded. For patients with AML and MDS, we collected cytogenetics data and classified them according to specific HSCT risk assessment (Armand et al, 2010; Armand et al, 2007) . For AML, patients with t(8;21), inv(16) and t(15;17) were classified as having favourable cytogenetics; patients with ≥4 abnormalities were considered as complex karyotype; all others patients were classified as intermediate risk. For MDS patients, an abnormality of chromosome 7 or a complex karyotype (≥4 abnormalities) were classified as adverse and all others as intermediate cytogenetic risk. Beside the cytogenetics risk, the disease subtype according to blast percentage was also considered for MDS stratification. The MDS subtypes, refractory anaemia with or without ringed sideroblasts and refractory cytopenia with multilineage dysplasia were considered as low risk. MDS with more than 5% of blasts (refractory anaemia with excess of blasts type 1 and type 2) were classified as high risk. Non-Hodgkin lymphoma (NHL) was considered as indolent if follicular lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma or hairy cell leukaemia and as aggressive if large B cell lymphoma and transformed indolent B-cell lymphoma; mantle cell lymphoma was considered by itself. Response to treatment was defined according standard criteria for each specific disease. Myeloablative conditioning regimen (MAC) was defined as a regimen containing total body irradiation (TBI) of more than 6 Gy, busulfan more than 8 mg/kg (oral) or 6Á4 mg/kg (intravenous). This study was approved by the Eurocord institutional review board. All patients or legal guardians provided written informed consent for research purposes. The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.
Statistical analysis
The primary endpoint was overall survival (OS), defined as time from UCBT to death from any cause. Patients alive at last contact or lost to follow-up were censored. Secondary endpoints were progression-free survival (PFS), relapse incidence (RI), non-relapse mortality (NRM) neutrophil engraftment (defined as neutrophil count ≥0Á5 9 10 progression or death from any cause, whichever came first. The probability of OS and PFS were estimated using the Kaplan-Meier method. RI and NRM were defined as time from UCBT to relapse and to death without relapse, respectively. Cumulative incidence was performed in a competing risk setting. Death without an event was the competing risk to calculate the probabilities of neutrophil and platelet engraftment, and acute and chronic GVHD. Death without progression or relapse was considered as competing risk for RI. Relapse was the competing event for NRM. Univariate hazard ratios were computed with Cox proportional-hazard method for OS and PFS and Fine and Gray's method for outcomes that considered competing events. Variables achieving a p-value <0Á10 in the univariate analyses for any outcome were included in the multivariate Cox proportional-hazard models, unless correlation with other clinical relevant variables precluded inclusion. Possible interactions between variables were tested in the final model. Type I error was settled at 0Á05 and p-values were two sided and considered statistically significant if less than 0Á05. Confidence intervals (CI) were estimated at 95%. Analysis was performed with SPSS 19 (IBM SPSS Statistics for Windows, Version 19Á0. IBM Corp, Armonk, NY) and R 3Á2Á3 (R Foundation for Statistical Computing, Vienna, Austria) software packages. Table I describes the characteristics of the 2350 patients. Median follow-up for survivors was 32 (range 2-120) months. Median age at UCBT was 43 (range 18-76) years. The majority of patients were male (55%) and recipient cytomegalovirus (CMV) serology was positive in 62%. Karnofsky performance status (PS) at UCBT was ≥90% in 62% of patients. AML was the most common disease (42% of patients); 45% of AML patients were transplanted in first complete remission while 38% of transplants were performed second or later complete remissions. The cytogenetic risk for AML patients was assessed as favourable in 9%, intermediate in 87% and adverse in 4%. For MDS patients, cytogenetic risk was adverse in 23% and intermediate in 77%. Most MDS patients were classified as having high-risk disease (81%). Fifty-two per cent of patients received a double UCBT and 48% a single UCBT. The conditioning regimen was MAC for 48% and reduced intensity conditioning (RIC) for 52% of patients. The most common regimen was cyclophosphamide + fludarabine + low dose total body irradiation (2 Gy) for RIC (73% of RIC) and thiotepa + busulfan + fludarabine for MAC (32% of MAC). Ciclosporin A (CsA) and mycophenolatemofetil (MMF) were used as GVHD prophylaxis in 61% of the patients. Anti-thymocyte globulin (ATG) was used in 41% of patients. Patients were stratified in 4 subgroups according to the refined DRI: low risk for 349 (15%), intermediate for 1403 (60%), high for 489 (20%) and very high for 109 patients (5%), as reported in Table II .
Results
Overall survival
Overall survival was 43 AE 1% at 2 years. According to the DRI, OS was 56 AE 3% for low risk, 46 AE 1% for intermediate risk, 28 AE 2% for high risk and 20 AE 4% for very highrisk patients (P < 0Á001) ( Fig 1A) . Two-year OS was 49 AE 5% for low, 45 AE 2% for intermediate, 28 AE 3% for high and 13 AE 5% for very high DRI (P < 0Á001) in patients who underwent MAC (Fig 2A) , whereas in the RIC setting, it was 59 AE 3% for low, 48 AE 2% for intermediate, 28 AE 3% for high and 29 AE 7% for very high DRI (P < 0Á001) (Fig 2B) . Univariate analysis hazard ratios (HRs) are reported in Table III and the probability of OS and PFS, as well as cumulative incidence for acute and chronic GVHD, relapse and NRM are provided in Table SI . In multivariate analysis (MVA), intermediate (HR = 1Á25, 95% CI 1Á02-1Á53, P = 0Á03), high (HR = 2Á12, 95% CI 1Á70-2Á65, P < 0Á001) and very high DRI (HR = 2Á85, 95% CI 2Á09-3Á89, P < 0Á001) were significantly associated with decreased survival compared with the low DRI group (Table IV) . Moreover, a positive CMV serology (HR = 1Á33, 95% CI 1Á16-1Á53, P < 0Á001), ATG use (HR = 1Á50, 95% CI 1Á33-1Á78, P < 0Á001), age at UCBT more than the median (HR = 1Á39, 95% CI 1Á22-1Á59, P < 0Á001), and a Karnofsky PS <90% (HR = 1Á50, 95% CI 1Á28-1Á69, P < 0Á001) were associated with a decreased OS.
Progression-free survival
The 2-year probability of PFS was 36 AE 1%. PFS was 46 AE 3%, 40 AE 1%, 22 AE 2% and 17 AE 4% for low, intermediate, high and very high DRI, respectively (P < 0Á001) (Fig 1B) . DRI was also statistically associated with different PFS when stratifying according to conditioning regimen intensity (P < 0Á001). MVA associated high (HR = 1Á90, 95% CI 1Á50-2Á34, P < 0Á001) and very high DRI (HR = 2Á25, 95% CI 1Á66-3Á03, P < 0Á001) with increased risk for lower PFS compared with the low DRI category (Table IV) . ATG use (HR = 1Á34, 95% CI 1Á26-1Á67, P < 0Á001), age more than the median at UCBT (HR = 1Á23, 95% CI 1Á08-1Á34, P = 0Á002), positive CMV serology (HR = 1Á29, 95% CI 1Á13-1Á46, P < 0Á001) and Karnofsky PS <90% (HR = 1Á41, 95% CI 1Á23-1Á62, P < 0Á001) were associated with decreased PFS. On the contrary, a UCBT performed after 2010 (HR = 0Á83, 95% CI 0Á73-0Á94, P = 0Á004) was associated with better PFS.
Engraftment and GVHD
The cumulative incidence of neutrophil engraftment at 60 days was 82% (95% CI: 81-84%). The median time for neutrophil engraftment was 22 (range: 6-89) days. Neutrophil engraftment was 88%, 84%, 76% and 64% for low, intermediate, high and very high DRI groups, respectively (P < 0Á001).
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The cumulative incidence of 100-day acute GVHD grade II-IV and grade III-IV was 30% (95% CI: 28-32%) and 13% (95% CI: 11-14%), respectively. Acute GVHD was 32%, 31%, 27%, 25% for low, intermediate, high and very high DRI groups, respectively (P = 0Á003). In MVA, ATG use was associated with lower incidence of acute GVHD (HR = 0Á39, 95% CI 0Á31-0Á50, P < 0Á001).
The cumulative incidence of chronic GVHD was 33% at 2 years (95% CI: 31-35%), with a median time of onset of 151 days. Among patients who experienced chronic GVHD, 56% had limited and 44% had extensive GVHD. The cumulative incidence of chronic GVHD was 36%, 34%, 28% and 27% for low, intermediate, high and very high DRI, respectively (P = 0Á01).
Relapse incidence and non-relapse mortality
The cumulative incidence of relapse was 28% at 2 years (95% CI: 26-30%). Relapse incidence was 17% for low DRI, 25% for intermediate, 42% for high and 38% for very high DRI (P < 0Á001). In MVA (Table IV) , intermediate (HR = 1Á49, 95% CI 1Á09-2Á03, P = 0Á01), high (HR = 3Á50, 95% CI 2Á50-4Á90, P < 0Á001) and very high DRI(HR = 3Á10, 95% CI 1Á90-4Á99, P < 0Á001) were associated with higher relapse risk compared to low DRI. Patients with a Karnofsky PS <90% (HR = 1Á33, 95% CI 1Á07-1Á64, P = 0Á008) and those who received a RIC regimen (HR = 1Á50, 95% CI 1Á21-1Á84, P < 0Á001) had a higher relapse risk.
The cumulative incidence of NRM at 2 years was 36% (95% CI: 34-38%). Overall, 58% of patients died, mostly of transplant-related mortality (34%). In MVA (Table IV) , very high DRI (HR = 1Á82, 95% CI 1Á24-2Á68, P = 0Á002), positive CMV serology (HR = 1Á44 95% CI 1Á20-1Á72, P < 0Á001), use of ATG (HR = 1Á78, 95% CI 1Á47-2Á15, P < 0Á001), age at transplantation more than the median (HR = 1Á42, 95% CI 1Á20-1Á70, P < 0Á001) and Karnofsky PS ALL, acute lymphoid leukaemia; AML, acute myeloid leukaemia, CLL, chronic lymphoid leukaemia, CML, chronic myeloid leukaemia; CR, complete remission, DRI, disease risk index; HL, Hodgkin lymphoma; MDS, myelodysplastic syndrome, MM, multiple myeloma; MPD, myeloproliferative disease; NHL, Non-Hodgkin Lymphoma; OS, overall survival; PFS, progression-free survival; PR, partial remission; VGPR, very good partial remission.
<90% (HR = 1Á50, 95% CI 1Á25-1Á80, P < 0Á001) were associated with higher NRM.
Discussion
Our study demonstrated that the DRI could be successfully used for the assessment of transplant risk in patients undergoing UCBT. The DRI was proposed and refined for registry studies on patients undergoing HSCT with different haematological diseases. Nevertheless, UCBT represented less than 10% of the cohort considered in the studies defining DRI (Armand et al, 2012; Armand et al, 2014) . The DRI has been tested in large and small cohorts, maintaining its ability to stratify patients undergoing HSCT, regardless of graft sources (Beauverd et al, 2014; Lim et al, 2015; Slack et al, 2013; Maka et al, 2017; He et al, 2017) . However, until now, the use of the DRI has not been described in a cohort of exclusively UCBT recipients.
In the current study, we confirmed that the DRI is able to stratify patients undergoing UCBT in 4 risk groups with the Conditioning regimen
aGVHD, acute graft-versus-host disease; ATG, anti-thymocyte globulin; cGVHD, chronic graft-versus-host disease; CI, confidence interval; CMV, cytomegalovirus; CsA, ciclosporin A; DRI, disease risk index; HR, hazard ratio; MAC, myeloablative conditioning regimen; MMF, mycophenolate mofetil; NRM, non-relapse mortality; OS, overall survival; PFS, progression-free survival; PS, performance status; Ref, reference; RIC, reduced conditioning regimen; SHR, sub-distribution hazard ratio for outcomes with competitive risk; UCBT, unrelated cord blood transplantation.
risk of treatment failure increasing from the low to the very high category. The DRI is able to group patients regardless of conditioning intensity regimen (Armand et al, 2012) . However, in our cohort, DRI stratification by conditioning regimen was similar as described in the previous study, except for patients with high and very high DRI receiving RIC conditioning (Fig 2B) . This may be explained by the limited number of patients included in the RIC very-high DRI subgroup (n = 45). Although this index has been developed and validated for OS (and, consequently, applies well to PFS) we did not observe a significant statistical difference between the low and intermediate DRI groups for PFS in MVA. Moreover, this index also seems able to separate patients according to relapse, even though the HR observed for the very high group is smaller than for the high DRI group. One possible explanation might be that assessment for disease recurrence varies according to the type of disease. For example, relapse assessment is mostly molecular based for chronic myeloid leukaemia, while it is often done through imaging techniques, such as positron emission tomography and magnetic resonance imaging, for lymphoproliferative diseases, making ascertainment of relapse less reliable. To demonstrate that, we applied DRI to a cohort restricted to AML patients only, and evaluated relapse according to DRI; we were able to observe well-stratified results, with risk increasing from the low to the very high DRI group (data not shown). Furthermore, the relative small number of patients in the highest risk category may also have contributed to the results observed. In the MVA for NRM, we also observed ordered results, but a statistically significant difference was only observed between the very high DRI and the baseline group (low DRI). However, it is important to emphasise that the modelling of the DRI was not established for RI and NRM.
Given that UCB remains an alternative source of stem cells, studies have often inadequate power due to the limited number of patients that can be included in the analyses. Stratification by DRI may permit the consideration of different diseases together, allowing for more patients to be included in the same study and, consequently, overcoming the limitation caused by small samples. Furthermore, the use of the DRI would possibly enable small centres to carry out important studies using their local data only, which might be otherwise impossible.
The DRI is a simple index that could be considered complementary to other scores, such as the HCT-CI (Armand et al, 2012) . Unfortunately, in our study, retrospective HCT-CI calculation of comorbidities was not possible as the necessary information for computing it is not consistently reported to our registry. On the other hand, the Karnofsky PS was available for the majority of patients and, even if less specific than the HCT-CI, it is able to quantify general wellness and correlate with disease status. In our study, a Karnofsky scores <90% at UCBT remained significantly associated with worse outcomes in MVA, independently of DRI. For OS, when stratifying according to DRI and Karnofsky PS (<90% vs. ≥90%), we observed a significant difference between the two groups in all the DRI categories except for patients with low DRI. This suggests that the combination of these two indexes, which are easily retrievable, might improve risk scoring for patients undergoing UCBT. Simple tools, such as the DRI, may eventually be used to help discussion with patients about the risk of the transplant procedure.
The DRI can be easily calculated with information promptly available from patient charts (e.g., disease type, status and cytogenetics) and could be adapted, with time, as we learn more about the biology of the different diseases. In the future, the DRI could include some important molecular information for diseases, such as AML, MDS and NHL, as new clinical markers become available (Kuwatsuka et al, 2009) . Moreover, the definition of complete remission may change with increasing knowledge about the impact of minimal residual disease, which may be reflected in the definition of DRI (Schlenk et al, 2008; Lugthart et al, 2008) . Our results confirm the prognostic value of the DRI as a valid and robust index system stratifying patients with different diseases according to survival risk in a large cohort of patients undergoing UCBT. Therefore, we support and recommend the use of this straightforward tool for analysing outcomes in UCBT studies.
